A pharma giant is moving past one patent cliff — but another is already looming

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. This story matters for Finance & Markets readers tracking option. Reported by cnbc.com. Read the full original at the source link below.